glp 1 agonist diabetes GLP-1 Receptor Agonists as Treatments for Type 2 GLP-1 Receptor Agonists and Research

doi: 10.3389/fendo.2022.1033479 Received 31 August 2022 Accepted 27 October 2022 Published 17 November 2022 Volume 13 - 2022 Edited by Jianbo Zhou, Beijing Tongren Hospital, Capital Medical University, China Reviewed by Finbarr P

This piece in 1993 also provided new insights into the biology of exendin, namely that exendin-4 was a full agonist of the human GLP-1 receptor, which Mojsov argues was crucial to convincing Amylin to develop exendin as a drug for diabetes (see below)

doi:10.1111/j.1463-1326.2010.01259.x 141

On Thursday, the Trump Administration and two major drugmakers announced an agreement to drastically reduce the cost of the drugs for people enrolled in Medicare and Medicaid, as well as for cash buyers

Traditional approaches to obesity management, including lifestyle interventions and older pharmacotherapies, have historically demonstrated limited long-term efficacy, creating an urgent need for more effective therapeutic options